@nile11.bsky.socialU.S. Obesity Rate Drops as GLP-1 Drug Prices Plunge
..................
https://nile1.com/u-s-obesity-rate-drops-as-glp-1-drug-prices-plunge/
..................
#eliLilly #exenatide #fda #genericDrugs #gilaMonster #glp-1 #johnEng #novoNordisk #obesityRate #semaglutide #tirzepatide #type2Diabetes #weg
@notexx.deđź’Š Abnehmpillen beflĂĽgeln Pharmabranche
Seit September gibt es Wegovy von Novo Nordisk in Deutschland als Tablette. Der Wirkstoff Semaglutid bleibt gleich, die Kosten liegen bei 170 bis 280 Euro monatlich.
@financiernews.bsky.socialNotable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Centene in focus
@businessam-fr.bsky.socialNovo Nordisk conclut un accord de licence de plusieurs milliards pour des injections à action prolongée contre l’obésité et le diabète #NovoNordisk #Obésité #Diabète #Santé #Médecine
@businessam.bsky.socialNovo Nordisk sluit miljardenlicentie voor langwerkende obesitas- en diabetesinjecties #NovoNordisk #Diabetes #Obesitas #Farmacie #Innovatie
@quartzmedia.bsky.socialICYMI: Novo Nordisk bets $1.3B on obesity shots you'd only take monthly #NovoNordisk #ObesityTreatment
@quartzmedia.bsky.socialNovo Nordisk bets $1.3B on obesity shots you'd only take monthly #NovoNordisk #ObesityTreatment
@newsen.bsky.socialNanexa and Novo Join Forces with EUR 1.165 Billion Licensing Agreement #Sweden #NovoNordisk #Uppsala #Nanexa #PharmaShell
@theworldeye.bsky.socialBREAKING: Novo Nordisk faces rising investor pressure as markets question the long-term growth pipeline beyond its dominant obesity treatments.
@jlsweekly.bsky.socialJLSW Daily Brief #99: Novo Nordisk's 2030 plan (5+ blockbusters, oral GLP-1) drew a cool reception; shares fell 7%+ on Sep 21. Amgen's dazodalibep met its Ph3 primary endpoint in Sjögren's.
#GLP1 #NovoNordisk #LifeSciencesJapan
https://jlsweekly.substack.com/p/jlsw-daily-brief-09920260923
@newsmason.bsky.social#trends today for 'donatella versace' 'hall of fame' & 'novo nordisk'
Click/Tap below:
www.newsmason.com?query=%22don...
www.newsmason.com?query=%22hal...
@richiewhites.bsky.socialWhy did Novo Nordisk fall more than 5%?
Shares dropped after the company’s new 2030 strategy failed to meet investor expectations.
#NovoNordisk #PharmaStocks #Healthcare #EuropeanStocks #NVO #MarketNews
@premarketprice.bsky.social$NVO drops 6% on 10.5x volume as its 2030 growth strategy disappoints investors, overshadowing positive CagriSema trial data. #NovoNordisk #Obesity
View Analysis: https://premarketprice.com/analysis/NVO
@kautious.comNovo Nordisk fell ~5%-7% after Capital Markets Day: 2026-30 growth “in line with peers” disappointed. Targets: >5 potential blockbusters by 2030, >DKK150bn pipeline sales by 2035; 4,000 more departures. Watch Lilly, semaglutide LOE and CagriSema (12.4% vs 9.1%). #NovoNordisk #obesity
@quartzmedia.bsky.socialICYMI: A century of medical breakthroughs compressed into a decade? #NovoNordisk #Anthropic
@4040rec.bsky.social
@thedailyfathom.bsky.socialBIOTECH · Novo Nordisk taps Anthropic's Claude to speed drug discovery
The Ozempic maker will use Anthropic's AI models and a new "Claude Science" tool to search for new medicines and speed up its own software work.
@richiewhites.bsky.socialCan AI speed up drug discovery?
Novo Nordisk is partnering with Anthropic to use advanced AI tools across drug research and development.
#NovoNordisk #Anthropic #AI #DrugDiscovery #Healthcare #Pharma #MarketNews
@quartzmedia.bsky.socialICYMI: Novo Nordisk drops 'Nordisk' as it scrambles to catch Eli Lilly #NovoNordisk #EliLilly
@nordic.skyen.live🇳🇴 Bodø/Glimt og Novo Nordisk får kritikk for samarbeidsavtalen og markedsføringen
#NordicNews #Nyheter #BodøGlimt #NovoNordisk #Samarbeid #Innenriks